Barinthus Biotherapeutics (BRNS) just unveiled an announcement.
Barinthus Biotherapeutics reported promising outcomes from its clinical trials on chronic hepatitis B treatments, showcasing significant progress in lowering HBsAg levels and achieving undetectable levels in some patients. The data, presented at the EASL Congress 2024, revealed that their treatments were well-tolerated with no serious adverse effects and led to many patients being eligible to discontinue standard therapy. This breakthrough has the potential to reshape chronic hepatitis B management and offers hope for more effective treatment options, making it an exciting development for investors and patients alike.
See more insights into BRNS stock on TipRanks’ Stock Analysis page.
